Compugen (NASDAQ: CGEN) — Company Overview, News & Financial Data
Compugen focuses on computational genomics and developing novel therapeutics for cancer and immune-related diseases using proprietary platforms.
Compugen
Compugen (TLV:CGEN), (NASDAQ:CGEN) is a pioneering company in the realm of computational genomics, dedicated to deciphering the complexities of the human genome to develop novel therapeutics for immunotherapy. This company focuses on the discovery and development of first-in-class therapeutics for cancer and immune-related diseases, leveraging its proprietary computational discovery platform. In alignment with its scientific advancements, Compugen is actively engaged in multiple projects aimed at identifying and characterizing potential drug targets that are novel, with an overarching goal to bring innovation to treatment paradigms. As a single-market listed entity, Compugen aims to expand its pipeline of therapeutic candidates and foster collaborations that enhance its research and development capabilities, striving to achieve breakthroughs for unmet medical needs.
Snapshot
Operations
Products and/or services of Compugen
- COM701, an immuno-oncology therapeutic antibody targeting PVRIG in clinical trials for various tumor types.
- BAY 1905254, a therapeutic antibody for solid tumors in collaboration with Bayer targeting ILDR2.
- CGEN-15001, a fusion protein for autoimmune diseases including multiple sclerosis and rheumatoid arthritis.
- COM902, a therapeutic antibody designed to enhance T cell activity in cancer treatment by targeting TIGIT.
Compugen executive team
- Anat Cohen-DayagExecutive Chair
- Eran OphirCEO, President & Director
- Pierre FerreChief Operating Officer
- Zurit LevineSenior Vice President of Business Development
- Michelle MahlerChief Medical Officer
- David SilbermanChief Financial Officer
- Lindsey TrickettHead of Investor Relations and Corporate Communications
- Eran Ben DorGeneral Counsel & Corporate Secretary
- Dorit AmitayVice President of Human Resources
- Rivka SchwartzVice President Research and Discovery
Key financials
Reported results for Compugen, in USD.
- Market cap
- 190.4M
- Revenue (TTM)
- 74M
- P/E ratio
- 5.3
- EPS (diluted, TTM)
- 0.4
- Dividend yield
- —
- Profit margin
- 47.6%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 72.8M | 31.3M | 35.3M | |
| 27.9M | -14.9M | -14.2M | |
| 33.5M | -13M | -18.8M | |
| 7.5M | -35.4M | -33.7M |